Reading ACXP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ACXP free→Reading ACXP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ACXP free→QuarterlyIQ Insights · ACXP
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On April 15, 2026, Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Registered Offering”) (i) 816,068 shares (the “Shares”) of common stock, par value $0.001 per share, of th…
Unregistered Sales of Equity Securities. The information set forth in
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding: the expected duration of, and the Company's plans and expectations with respect to, the Salary Reductions and the Director Cash Reductions; the Company's planned clinical development initiative to expand the ibezapolstat program into rCDI, incl…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 9, 2026, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Acurx Pharmaceuticals, Inc. (the “Company”) approved, and the executive officers listed below voluntarily agreed to, reductions to their base salaries (the “Salary Reductions”) as part of broader leadership compensation alignment measures. The C…
Material Modifications to Rights of Security Holders. To the extent required by Item 3.03, the disclosure set forth in
Unregistered Sales of Equity Securities. The Company issued the New Warrants and the Wainwright Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2). Neither the issuance of the New Warrants, the Wainwright Warrants, the New Warrant Shares nor the share underlying the Wainwright Warrants have been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or…
Entry into a Material Definitive Agreement. On June 17, 2025, Acurx Pharmaceuticals, Inc. (the “Company”), entered into a warrant inducement agreement (the “Letter Agreement”) with a certain holder (the “Holder”) of existing (i) series A warrants to purchase 1,230,769 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) series B warrants to purchase 548,000 shares of Common Stock, (iii) series C warrants to purchase 1,333,333 shares of Common Stock, and…
Results of Operations and Financial Condition. On May 13, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025 and providing a business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for pur…
Entry into a Material Definitive Agreement. On May 8, 2025, Acurx Pharmaceuticals, Inc. (the “Company”, “we”, “us” and “our”) entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park committed to purchase up to $12.0 million in shares of our common stock, $0.001 par value per share. Concurrently with the execution of the Purchase Agreement on May 8, 2025, we also entered into a registration rights agreeme…
In the Purchase Agreement, Lincoln Park represented to the Company, among other things, that it is an “accredited investor” as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”). The shares of common stock that were issued and may be issued to Lincoln Park under the Purchase Agreement were not and will not be registered under the Securities Act or qualified under any state securities laws. Such shares were issued and will…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 25, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’…
Results of Operations and Financial Condition. On March 18, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2024 and providing a business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed t…
Unregistered Sales of Equity Securities. The information set forth in
Entry into a Material Definitive Agreement. On March 6, 2025, Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor named therein (the “Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investor (the “Registered Offering”) (i) 2,150,000 shares (the “Shares”) of common stock, par value $0.001 per s…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 24, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 31 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notice has no imme…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.